US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

BIIB

Biogen (BIIB)

Biogen Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:BIIB

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/31	05 : 51	GlobeNewswire Inc.	Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS	NASDAQ:BIIB	Biogen Inc
2024/05/23	20 : 40	IH Market News	OpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More News	NASDAQ:BIIB	Biogen Inc
2024/05/22	20 : 30	GlobeNewswire Inc.	Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences	NASDAQ:BIIB	Biogen Inc
2024/05/16	20 : 30	GlobeNewswire Inc.	Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis	NASDAQ:BIIB	Biogen Inc
2024/05/16	20 : 30	PR Newswire (US)	Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis	NASDAQ:BIIB	Biogen Inc
2024/05/15	08 : 33	GlobeNewswire Inc.	Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status	NASDAQ:BIIB	Biogen Inc
2024/05/15	08 : 30	PR Newswire (US)	Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status	NASDAQ:BIIB	Biogen Inc
2024/05/02	20 : 30	GlobeNewswire Inc.	Biogen Reports Progress on Corporate Responsibility Priorities	NASDAQ:BIIB	Biogen Inc
2024/04/01	08 : 30	PR Newswire (US)	Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	NASDAQ:BIIB	Biogen Inc
2024/03/06	21 : 30	GlobeNewswire Inc.	New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy	NASDAQ:BIIB	Biogen Inc
2024/03/05	06 : 15	GlobeNewswire Inc.	Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting	NASDAQ:BIIB	Biogen Inc
2024/02/27	09 : 54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/02/23	21 : 00	GlobeNewswire Inc.	Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP	NASDAQ:BIIB	Biogen Inc
2024/02/23	00 : 12	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BIIB	Biogen Inc
2024/02/22	11 : 39	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/02/22	11 : 36	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/02/22	11 : 33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/02/22	11 : 31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/02/22	11 : 29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/02/22	11 : 28	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/02/22	11 : 27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/02/22	00 : 24	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BIIB	Biogen Inc
2024/02/21	11 : 13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/02/14	08 : 14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/02/14	08 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/02/14	08 : 04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/02/14	08 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/02/14	08 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/02/14	08 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc
2024/02/14	07 : 56	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BIIB	Biogen Inc

Showing the most relevant articles for your search:NASDAQ:BIIB

1 2 3 4 5 6 7 8 9 10 次へ >>

BNP Paribas Issuance

Lyrical International Va...

BNP Paribas Issuance

Societe Generale Effekten

Baroyeca Gold and Silver

Amundi Index Solutions

Sunshine Agri Tech

Bnp Paribas Issuance

BNP Paribas Issuance

Gama Explorations (QB)

Vontobel Financial Produ...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約